

<https://helda.helsinki.fi>

---

## Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status

Parente, Erika B

BioMed Central

2020-05-19

---

Cardiovascular Diabetology. 2020 May 19;19(1):68

---

<http://hdl.handle.net/10138/315204>

---

*Downloaded from Helda, University of Helsinki institutional repository.*

*This is an electronic reprint of the original article.*

*This reprint may differ from the original in pagination and typographic detail.*

*Please cite the original version.*

ORIGINAL INVESTIGATION

Open Access



# Relationship between ABO blood groups and cardiovascular disease in type 1 diabetes according to diabetic nephropathy status

Erika B. Parente<sup>1,2,3,4</sup> , Valma Harjutsalo<sup>1,3,4,5</sup>, Markku Lehto<sup>1,3,4</sup>, Carol Forsblom<sup>1,3,4</sup>, Niina Sandholm<sup>1,3,4</sup>, Per-Henrik Groop<sup>1,3,4,6\*</sup> and on behalf of the FinnDiane Study Group

## Abstract

**Background:** ABO blood groups have previously been associated with cardiovascular disease (CVD) in the general population. This study aimed to investigate the potential relationship between ABO blood groups and CVD in individuals with type 1 diabetes according to diabetic nephropathy (DN) status.

**Methods:** Adults with type 1 diabetes (4531 individuals) from the FinnDiane Study were evaluated. DN was determined by two out of three measurements of urinary albumin excretion rate. Albuminuria was defined as an excretion rate above 20 µg/min. CVD events were identified by linking the data with the Finnish Care Register for Health Care and the Finnish Cause of Death Register. Follow-up ranged from the baseline visit until a CVD event, death or the end of 2017. The impact of ABO blood groups on CVD risk was estimated by multivariable Cox-regression analyses adjusted for traditional risk factors.

**Results:** At baseline, the median age was 38.5 (IQR 29.2–47.9) years, 47.5% were female and median duration of diabetes was 20.9 (11.4–30.7) years. There were 893 incident ischemic heart disease (IHD) events, 301 ischemic strokes (IS), and 415 peripheral artery disease (PAD) events during a median follow up of 16.5 (IQR 12.8–18.6) years. The A blood group showed the highest risk of IHD versus the O blood group, when microalbuminuria was present. Comparing the population with microalbuminuria with those with normoalbuminuria, only the A blood group elevated the risk of IHD. This increased risk was neither explained by the *FUT2* secretor phenotype nor by the A-genotype distribution. The risk of IS or PAD was no different among the ABO blood groups regardless of diabetic nephropathy stage.

**Conclusion:** The A blood group is a risk factor for IHD in individuals with type 1 diabetes and microalbuminuria.

**Keywords:** Type 1 diabetes, Diabetic nephropathy, Cardiovascular disease, Blood group

## Background

Cardiovascular disease (CVD) is the major cause of death among people with diabetes worldwide and the ABO blood groups have been associated with CVD in several studies [1–3]. The first time the ABO blood groups were shown to be associated with CVD was in 1962 [4] when

the A and B blood groups were linked to ischemic heart disease (IHD). Recently, it was described that ABO blood groups are associated with increased cardiovascular risk in individuals with familial hypercholesterolemia [5]. The majority of previous studies have indicated that the O blood group confers the lowest risk of thrombotic events, although the group with the highest risk is still controversial and depending on the studied population [1–3, 6].

The reasons why the ABO blood group is a risk factor of CVD is still under investigation. ABO antigens are not expressed only on the surface of red blood cells but

\*Correspondence: per-henrik.groop@helsinki.fi

<sup>1</sup> Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland

Full list of author information is available at the end of the article



© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

also on epithelial and endothelial cells, T-cells, B-cells and platelets [8]. These antigens might also be found in the circulation and body secretions, if the individual has the *FUT2* gene secretor phenotype [8]. The interaction between ABO blood antigens and adhesion molecules, such as the soluble InterCellular Adhesion Molecule 1 (sICAM-1), may differ depending on the A blood group subtypes A1 or A2, which interferes with the leucocyte endothelium adhesion [9]. Different levels of the von Willebrand factor (vWF) [10] and HDL-cholesterol concentrations [11] have also been suggested to explain the relationship between ABO blood groups and CVD risk.

CVD is a major cause of premature mortality in individuals with type 1 diabetes, especially if diabetic nephropathy (DN) is present [12–14]. Acute diabetic complications drive the mortality rate during the first years of living with type 1 diabetes, but IHD becomes the main cause of premature mortality of those with longer duration of diabetes [15]. Although there are several well-known CVD risk factors in type 1 diabetes, the potential impact of the ABO blood groups on this risk has never been studied in this population. This study therefore aimed to explore this unanswered question taking different DN stages into account.

## Methods

### Research design

This is an observational prospective study to evaluate the relationship between ABO blood groups and CVD in type 1 diabetes according to DN stage as part of the ongoing Finnish Diabetic Nephropathy (FinnDiane) Study, which is a nationwide, prospective, multicenter study aiming to identify risk factors for type 1 diabetes complications. The CVD risk of ABO blood groups was compared according to the various stages of DN.

### Study population

The FinnDiane Study has since 1997 recruited and characterized individuals with type 1 diabetes 18 years or older from 93 centers across Finland and the recruitment of new study participants is still ongoing. This analysis included 4531 individuals with type 1 diabetes with urinary albumin excretion rate (UAER) data and information on ABO blood groups available. Type 1 diabetes was defined as age at onset of diabetes under 40 years and permanent insulin treatment initiated within a year from the diabetes diagnosis. The study protocol followed the principles of the Declaration of Helsinki as revised in 2000 and was approved by the Ethical Committee of Helsinki and Uusimaa Hospital District. Written informed consents were obtained from each FinnDiane participant. The baseline visit occurred between the years 1997 and 2015 and at which the participants underwent a

thorough clinical examination, blood and urine samples were collected and several questionnaires including specific questions about lifestyle habits were completed by the participants.

### DN stage

The stage of DN was based on the individuals' urinary albumin excretion rate (UAER) from timed overnight and 24 h urine (mg/24 h) collections. Normoalbuminuria was defined as a UAER < 20 µg/min or < 30 mg/24 h in at least two out of three urine samples. Microalbuminuria was defined as UAER ≥ 20 and < 200 µg/min or ≥ 30 and < 300 mg/24 h, macroalbuminuria as UAER ≥ 200 µg/min or ≥ 300 mg/24 h and end-stage renal disease (ESRD) as dialysis or kidney transplantation.

### ABO blood groups

The ABO blood groups were determined based on genetic variants coding for or tagging the O (rs8176719 deletion allele), B (rs8176746 A allele), and A (rs8176747 G allele) groups [16]. The A1 versus A2 subgroup was defined based on the rs8176750 C allele [17]. Secretor status was defined based on the *FUT2* rs601338 AG/GG genotypes [18]. Genotyping was done with Human Core Exome Bead Chips 12–1.0, 12–1.1 or 24–1.0 (Illumina, San Diego, CA, USA), with genotype imputation using the 1000 genomes reference panel, as described earlier [19]. The rs8176746 was directly genotyped, and the other variants were imputed with high quality ( $r^2 \geq 1.0$ ); most likely genotypes were used for the imputed variants.

### CVD

With CVD events we refer to IHD, ischemic stroke (IS) and peripheral arterial disease (PAD). The corresponding international classification of disease (ICD) codes are listed in the Additional file 1: table S1. CVD events were identified by linking the data with the Finnish Care Register for Health Care and the Finnish Cause of Death Register. Participants that had had a CVD event before the baseline visit were excluded. The follow-up period ranged from the baseline visit until the occurrence of the first CVD event, death or the end of 2017.

### Utilization of antibiotic drugs

We used the Finnish Drug Prescription Register of antibiotic purchase per person per year to investigate the distribution of the number of infections per person per year among the ABO blood groups.

### Statistical analysis

Data on categorical variables are presented as frequencies, while continuous variables are shown as means ( $\pm$  standard deviation, SD) for normally distributed

**Table 1** Baseline characteristics according to ABO blood groups

	O n = 1333 (29.4%)	A n = 2012 (44.4%)	B n = 796 (17.6%)	AB n = 390 (8.6%)	p value
Sex (female %)	46.5	47.5	48.0	50.3	0.62
Age (years)	38.0 (29.2–47.5)	38.2 (29.2–47.8)	39.2 (29.1–48.4)	39.3 (29.0–48.5)	0.81
Duration of diabetes (years)	21.5 (11.3–30.8)	20.4 (11.4–30.3)	21.3 (12.0–30.7)	21.0 (11.2–32.7)	0.47
HbA <sub>1c</sub> (%)	8.4 ± 1.5	8.4 ± 1.5	8.4 ± 1.5	8.3 ± 1.4	0.46
Smoking history (%)	46.4	47.5	47.4	46.9	0.95
Body Mass Index (kg/m <sup>2</sup> )	25.1 ± 3.5	25.1 ± 3.8	25.0 ± 3.5	25.0 ± 3.9	0.81
Waist-to-hip ratio	0.87 ± 0.08	0.87 ± 0.09	0.87 ± 0.09	0.87 ± 0.08	0.71
Systolic blood pressure (mmHg)	134 ± 18	135 ± 19	134 ± 18	135 ± 20	0.44
Diastolic blood pressure (mmHg)	80 ± 10	80 ± 10	80 ± 10	79 ± 10	0.74
Total cholesterol (mmol/l)	4.90 ± 0.99	4.95 ± 1.01	4.87 ± 0.93	4.95 ± 0.95	0.17
HDL cholesterol (mmol/l)	1.32 ± 0.38	1.33 ± 0.39	1.35 ± 0.40	1.36 ± 0.41	0.25
Triglycerides (mmol/l)	1.06 (0.78–1.51)	1.03 (0.78–1.52)	1.01 (0.77–1.45)	1.04 (0.75–1.40)	0.16
Hs-CRP (mg/l)	4.5 ± 9.4	4.6 ± 9.4	4.2 ± 8.5	4.7 ± 9.0	0.64
DN groups					0.42
Normoalbuminuria (n, %)	862 (64.7)	1311 (65.2)	505 (63.4)	253 (64.9)	
Microalbuminuria (n, %)	178 (13.4)	251 (12.5)	109 (13.7)	44 (11.3)	
Macroalbuminuria (n, %)	199 (14.9)	272 (13.5)	124 (15.6)	55 (14.1)	
ESRD (n, %)	94 (7.0)	178 (8.8)	58 (7.3)	38 (9.7)	
Laser treatment (%)	34.7	31.9	35.2	34.3	0.22
Lipid lowering therapy (%)	13.0	14.6	11.6	15.0	0.36
Blood Pressure lowering therapy (%)	38.8	39.3	39.0	40.0	0.98
ACE/ARB users (%)	30.3	31.0	30.7	30.5	0.98
FUT2 Secretor (%)	81.4	82.7	82.4	83.5	0.72
Antibiotic purchases per person year	0.62 (0.30–1.46)	0.63 (0.28–1.33)	0.59 (0.26–1.34)	0.60 (0.28–1.30)	0.90
IHD (n, %)	82 (6.2)	132 (6.6)	49 (6.2)	30 (7.7)	0.50
Socioeconomic status					
Blue collar worker (%)	56.9	58.0	60.7	57.0	0.48
White collar worker (%)	32.6	30.2	30.4	32.3	
Others (%)	3.6	4.3	2.8	3.2	
Not known (%)	6.9	7.5	6.1	7.6	
Alcohol consumption (g/week)	48.0 (24.0–84.0)	48.0 (24.0–84.0)	42.0 (24.0–84.0)	36.0 (24.0–84.0)	0.06
Abstainers (%)	26.5	27.1	26.8	26.7	0.18
Missing data (%)	9.3	9.8	9.8	6.2	0.76

Data are given as mean ± SD or median and interquartile range

HbA<sub>1c</sub> glycated hemoglobin, Hs-CRP high-sensitivity C-reactive protein, DN diabetic nephropathy, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blockers, HDL high-density lipoprotein, FUT2 fucosyltransferase-2, IHD ischemic heart disease

p value refers to ANOVA, Kruskal–Wallis test or  $\chi^2$ -test adjusted for age at baseline when applicable. Comparisons are made among ABO blood groups

values and variables with skewed distribution as medians (interquartile ranges, IQR). Between-group comparisons were performed with Chi squared test, ANOVA for normally distributed continuous variables, otherwise by the Kruskal–Wallis test.

The impact of the ABO blood groups on CVD risk was estimated by multivariable Cox-regression analyses adjusted for the following traditional risk factors: age at diabetes diagnosis, body mass index (BMI), duration of diabetes, systolic blood pressure (SBP), HDL cholesterol,

triglycerides, HbA<sub>1c</sub>, sex, severe diabetic retinopathy (defined as laser treatment) and history of smoking. Interaction between ABO blood groups and DN status was tested and since it was significant, the analyses were conducted separately for each DN group. However, the interaction between the ABO blood groups and sex was not significant and therefore these analyses were conducted by pooling men and women. The assumption of the proportional hazards was tested by Schoenfeld residuals against time and testing a non-zero slope

by including time-covariate interactions. In case the assumption did not hold the interaction between the covariate and time was added to the final model. All analyses were performed with Statistical Analysis System version 9.4 (SAS Institute, Cary, NC, USA).

## Results

At baseline, the median age was 38.5 (IQR 29.2–47.9) years, 47.5% were female and the median duration of diabetes was 20.9 (11.4–30.7) years. There were 893 incident IHD events, 301 IS and 415 PAD events during 62,326 person-years for IHD, 68,137 for IS and 67,118 for PAD during a median follow up of 16.5 (IQR 12.8–18.6) years.

Baseline characteristics such as the prevalence of IHD, FUT2 secretor phenotype, number of antibiotic purchases per person per year, serum hs-CRP level, DN stages and other well-known CVD risk factors were no different between the ABO blood groups (Table 1). ABO genotypes were also equally distributed according to the DN stages (Fig. 1).

Among individuals with microalbuminuria, those with the A blood group showed the highest risk of IHD compared to those with O blood group (HR 1.93, CI 95% 1.24–3.00) (Fig. 2). A similar result was seen in the microalbuminuric group comparing the non-O blood group (A, B and AB) with the O blood-group (HR 1.81, CI 95% 1.15–2.84) (Additional file 1: Table S2). There was no difference in the risk of IHD between the ABO blood

groups at any of the other DN stages (Fig. 2 and Additional file 1: Table S2).


Comparing individuals with microalbuminuria to those with normoalbuminuria, only the A blood group showed a greater risk of IHD (HR 1.94, CI 95% 1.41–2.67,  $p < 0.0001$ ) (Fig. 3).

Among the individuals with the A blood group, the incidence of IHD events (29.3% vs 10.9%,  $p < 0.0001$ ), levels of serum high sensitivity C-reactive protein (hs-CRP) (2.51 mg/l vs 1.71 mg/l,  $p < 0.001$ ) and the number of antibiotic purchase per person per year (0.78 vs 0.47,  $p < 0.001$ ) were greater in the individuals with microalbuminuria compared to those with normalbuminuria, although there was no difference in the prevalence of FUT2 secretor phenotype ( $p = 0.82$ ), nor the A1/A2 subtype distribution ( $p = 0.87$ ) (Additional file 1: Table S3).

The risk of IS and PAD was no different among the ABO blood groups, regardless of DN status (Additional file 1: Tables S4, S5).


## Discussion

This is the first study to show that the A blood group is a risk factor for IHD in a large cohort of individuals with type 1 diabetes and microalbuminuria. The risk was 93% higher compared to the risk in those with the O blood group at the same DN stage. The risk of IHD was also 81% higher when the non-O blood group carriers were compared to the O blood group in those with microalbuminuria. Of note, the risk of the non-O blood group



$p=0.58$ , no difference in the distribution according to DN stages.

**Fig. 1** Distribution of ABO genotype by DN stages




**Fig. 2** IHD risk of ABO blood groups stratified by DN stages

was driven by the high risk of the A blood group. Furthermore, individuals with microalbuminuria and the A blood group had a 94% higher risk of IHD compared to those with normoalbuminuria.

Although the O blood group has often been considered as the reference group with the lowest risk of ischemic CVD, the blood group with the highest risk has also varied depending on the studied population. Whether this is due to ethnical differences is not known. On one hand, a cross-sectional study with 299 individuals from Africa showed that the A blood group is the one with the highest risk of ischemic CVD, defined as coronary artery disease, myocardial infarction or IS [20]. On the other hand,

a study on 64,686 blood donors from Canada showed that the AB blood group is the one carrying the highest risk of hospitalization or death due to thrombotic events such as coronary, cerebrovascular or peripheral disease [21]. A study from Italy on a small cohort of 249 blood donors showed that the non-O blood group was the group with the highest risk of cardiovascular events [22], and similar results were obtained from a larger study from Sweden and Denmark with 1.5 million blood donors showing that individuals with the non-O blood group had higher incidence of both venous and arterial thromboembolic events than the O blood group [23]. Finally, a meta-analysis also described the A blood-group



HR: hazard ratio; CI: confidence interval; Analyses were adjusted for age at diabetes diagnosis, duration of diabetes, BMI, systolic blood pressure, HDL cholesterol, triglycerides, HbA<sub>1c</sub>, sex, severe diabetic retinopathy (laser treatment) and smoking.

**Fig. 3** IHD risk between individuals with normo and microalbuminuria according to ABO blood groups

[2] and the non-O blood group [2, 3] as the highest risk groups for coronary artery disease, data that are in concordance with our results. However, the question arises, why does the A blood group in our and other populations confer an increased risk of IHD, and why is this risk particularly seen in those individuals with type 1 diabetes and microalbuminuria.

#### ABO genotype and CVD

In order to answer this question we analyzed the ABO genotype distribution, especially the A1 and A2, among the different DN groups, since it has been described that the A1 subtype confers higher thrombogenic risk than the A2 subtype [23, 24], but we found no difference in

the genotype distribution in our population. It has been suggested that the A blood group antigen can bind to endothelial cells and thereby contribute to cytoadherence, and the mechanism might involve antigen glycosylation that interacts with the p-selectin/ICAM-1 [25]. In this respect, the risk difference among the A blood group individuals could possibly be explained by lower levels of sICAM-1 in the A1 compared to the A2 carriers [9]. Unfortunately, we did not have access to any sICAM-1 measurements from our population.

#### FUT2 secretor phenotype and CVD

We also evaluated the frequency of *FUT2* secretors and non-secretors, in order to explore the interactions



between the ABO antigens and the endothelial adhesion molecules. It has been suggested that only people with a functional *FUT2* gene can secrete ABO antigens into the body fluids, a phenomenon characterizing the *FUT2* secretor phenotype [26]. However, we did not find any differences in the distribution of *FUT2* secretor phenotype among the different ABO blood groups nor between the A blood group individuals with normo- or microalbuminuria in our population.

### Infections and CVD

It is of note that there is a clear association between bacterial infections and the risk of CVD [27, 28], and it is also well-known that bacterial infections have both a direct and an indirect effect on the atherosclerotic process [27], an inflammatory condition that starts with lesions and dysfunction of the endothelium [28]. As previous data from our group showed that individuals with type 1 diabetes have a higher risk of bacterial infections [29], thus, we explored whether this increased risk of infections may be due to the ABO blood group and whether the ABO blood group could also have an impact on the risk of CVD in this population. Although there were no differences in the prevalence of infections among the various blood groups (Table 1), the individuals with the A blood group and microalbuminuria had a higher incidence of IHD events, higher hs-CRP levels and a higher number of antibiotic purchases per person per year compared to the individuals with normoalbuminuria with the same blood group. Thus, the inflammation/infection could be a possible mediator of this relationship between the A blood group, microalbuminuria and IHD. However, we do not know how inflammation after or during a bacterial infection, or how the microalbuminuric state might facilitate adhesion of the A-antigen to the endothelium.

### Lipids and CVD

Given the well-known associations between the lipids and CVD, we also investigated the distribution of total cholesterol, HDL-cholesterol and triglycerides among the ABO blood groups. However, there were no differences between the groups. In contrast, a Chinese study with 6476 individuals, showed that about 10% of the effect of the non-O blood group on the risk of coronary artery disease was mediated by its influence on LDL-cholesterol [30]. In an Indian study, the AB blood group was associated with high concentrations of HDL-cholesterol, while the O blood group was associated with low concentrations [11]. Besides these ethnical differences, there might be additional factors involved in type 1 diabetes such as proteomic alterations of the HDL-cholesterol [31] and a higher prevalence of coronary atherosclerosis compared to controls [32] that might increase the risk of CVD.

Whether the ABO blood groups may have an impact on such alterations of the HDL-cholesterol molecules is not known.

### Other factors and CVD

There are also other factors that might interact with the ABO blood group antigens and thereby modulate the risk of ischemic CVD. For instance, it is well-known that the non-O blood group is associated with lower clearance of the vWF. Reduced clearance of vWF leads to a subsequent elevation of its plasma concentrations, which in turn enhances the chance of thrombotic events [3, 10, 33]. Other explanations for the high risk of CVD in the non-O blood group could be the size of the platelets [34], the interaction between the red blood cell surface antigens (A, B, AB) with sICAM [3, 9, 25], p-selectin [25], E-selectin [35, 36] or plasma glycine [37, 38]. Unfortunately, none of these factors were measured in the present study.

### ABO blood groups and the risk of IS and PAD

In our analysis, the ABO blood groups were neither a relevant risk factor for IS nor PAD. Conversely, the MESA study showed that the A blood group was associated with a greater risk of PAD in African Americans, although it was not significant in Chinese, non-Hispanic white or Hispanic Americans [39]. Since our study was performed in a Caucasian Finnish population, race/ethnicity factors might be involved in the observed differences. Regarding the risk of IS, our results are similar to a Canadian study [21] in which any ABO blood group was a risk factor for hospitalization or death because of cerebrovascular disease. In the Canadian study, the ABO blood group was a risk factor for cerebrovascular disease only, when it was analyzed together with coronary artery disease. The smaller number of incident IS ( $n=301$ ) compared to the number of IHD ( $n=893$ ) could be a reason, why we did not detect any statistically significant difference in the IS risk.

Notably, in this study the ABO blood groups had no impact on CVD risk in individuals with advanced kidney disease, such as macroalbuminuria or ESRD. It is possible that advanced kidney disease in itself is such a strong risk factor for CVD that it might overrule any other thrombotic risk factor, for instance the ABO blood groups.

### Limitations and strengths

A clear limitation is that we did not have information on vWF, sICAM-1, LFA-1, E-selectin, p-selectin, plasma glycine or platelet size that could have helped us further explore the relationship between the ABO blood groups and the thrombotic risk. Another limitation is the small number of individuals in the AB blood group that



limited our possibility to draw any conclusions regarding the CVD risk of this group.

Albeit these limitations, the strength of this study is its novelty to demonstrate that the A blood group is a risk factor for IHD in a large cohort of individuals with type 1 diabetes and microalbuminuria, a group that already carries a high CVD risk.

## Conclusion

The A blood group is an additional risk factor for IHD in individuals with type 1 diabetes and microalbuminuria, independently of the traditional CVD risk factors. In contrast, the ABO blood groups do not confer additional risk regarding IS or PAD in individuals with type 1 diabetes, regardless of the DN stage. Our results motivate further studies to elucidate the precise mechanism of the relationship between the A blood group, microalbuminuria and IHD. From a clinical perspective, our results raise the question, whether the ABO blood groups should be considered as an additional risk factor when CVD risk is assessed in individuals with type 1 diabetes and microalbuminuria.

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s12933-020-01038-z>.

**Additional file 1: Table S1.** Specific codes used for the cardiovascular outcomes from the relevant registries. **Table S2.** IHD risk of ABO blood groups stratified by nephropathy stages. **Table S3.** Comparison between individuals with normo and microalbuminuria with A-blood-group. **Table S4.** Ischemic stroke risk of ABO blood groups stratified by nephropathy stages. **Table S5.** Peripheral artery disease risk of ABO blood groups stratified by nephropathy stages. **Table S6.** List of physicians and nurses at each of the FinnDiane centers participating in patient recruitment and characterization.

## Abbreviations

CVD: Cardiovascular disease; IHD: Ischemic heart disease; IS: Ischemic stroke; PAD: Peripheral artery disease; sICAM-1: Soluble InterCellular Adhesion Molecule 1; vWF: von Willebrand factor; DN: Diabetic nephropathy; UAER: Urinary albumin excretion rate; ESRD: End-stage renal disease; SD: Standard deviation; IQR: Interquartile ranges; HR: Hazard ratio; CI: Confidence interval; BMI: Body mass index; SBP: Systolic blood pressure; CRP: C-reactive peptide; LFA-1: Lymphocyte function-associated antigen-1; LDL: Low-density lipoprotein; HDL: High-density lipoprotein.

## Acknowledgements

The authors would like to acknowledge all physicians and nurses at each FinnDiane center participating in patient recruitment and characterization (Additional file 1: Table S6).

## Authors' contributions

EBP and PHG were responsible for study design. EBP was responsible for manuscript preparation. VH was responsible for statistical analysis. NS was responsible for genetic analysis. PHG, EBP, VH, ML interpreted the results and contributed to writing the manuscript. CF contributed to acquisition of the data and critical revision of the manuscript. All authors read and approved the final manuscript.

## Funding

This research was funded by grants from the Folkhälsan Research Foundation, Academy of Finland (299,200 and 316,664), Wilhelm and Else Stockmann Foundation, Liv och Hälsa Society, Helsinki University Central Hospital Research Funds (EVO), Novo Nordisk Foundation (NNF OC0013659), Juvenile Diabetes Research Foundation (JDRF, 17-2013-7), an EFSD award supported by EFSD/Sanofi European Diabetes Research Programme in Macrovascular Complications, and Diabetes Research Foundation.

## Availability of data and materials

No data are available. The ethical statement and the informed consent do not allow for free data availability.

## Ethics approval and consent to participate

The study protocol was in accordance with the principles of the Declaration of Helsinki as revised in 2000 and was approved by the Ethical Committee of Helsinki and Uusimaa Hospital District. Written informed consents were obtained from each FinnDiane patient.

## Consent for publication

Not applicable.

## Competing interests

EBP has received lectures fee from Eli Lilly, Astra Zeneca, Sanofi, Boehringer Ingelheim and is an advisory board member of Sanofi. P-H.G. reports receiving lecture honorariums from Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Elo Water, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, PeerVoice, Sanofi, SCIARC and being an advisory board member of AbbVie, Astellas, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. No other potential conflicts of interest relevant to this article were reported.

## Author details

<sup>1</sup> Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. <sup>2</sup> Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil. <sup>3</sup> Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. <sup>4</sup> Abdominal Center, Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. <sup>5</sup> National Institute for Health and Welfare, Chronic Disease Prevention Unit, Helsinki, Finland. <sup>6</sup> Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

Received: 13 February 2020 Accepted: 9 May 2020

Published online: 19 May 2020

## References

- Zhang H, Mooney CJ, Reilly MP. ABO blood groups and cardiovascular diseases. *Int J Vasc Med*. 2012;2012:641917.
- Chen Z, Yang SH, Xu H, Li JJ. ABO blood group system and the coronary artery disease: an updated systematic review and meta-analysis. *Sci Rep*. 2016;6:23250.
- He M, Wolpin B, Rexrode K, Manson JE, Rimm E, Hu FB, et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. *Arterioscler Thromb Vasc Biol*. 2012;32(9):2314–20.
- Bronte-Stewart B, Botha MC, Krut LH. ABO blood groups in relation to ischaemic heart disease. *Br Med J*. 1962;1(5293):1646–50.
- Paquette M, Dufour R, Baass A. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. *J Clin Lipidol*. 2018;12(2):383.
- Gong P, Luo SH, Li XL, Guo YL, Zhu CG, Xu RX, et al. Relation of ABO blood groups to the severity of coronary atherosclerosis: an Gensini score assessment. *Atherosclerosis*. 2014;237(2):748–53.
- Yip SP. Sequence variation at the human ABO locus. *Ann Hum Genet*. 2002;66(Pt 1):1–27.
- Ewald DR, Sumner SC. Blood type biochemistry and human disease. *Wiley Interdiscip Rev Syst Biol Med*. 2016;8(6):517–35.
- Paré G, Chasman DI, Kellogg M, Zee RY, Rifai N, Badola S, et al. Novel association of ABO histo-blood group antigen with soluble ICAM-1:

- results of a genome-wide association study of 6,578 women. *PLoS Genet*. 2008;4(7):e1000118.
10. Cheung KL, Bouchard BA, Cushman M. Venous thromboembolism, factor VIII and chronic kidney disease. *Thromb Res*. 2018;170:10–9.
  11. Biswas S, Ghoshal PK, Halder B, Mandal N. Distribution of ABO blood group and major cardiovascular risk factors with coronary heart disease. *Biomed Res Int*. 2013;2013:782941.
  12. Harjutsalo V, Maric-Bilkan C, Forsblom C, Groop PH. Impact of sex and age at onset of diabetes on mortality from ischemic heart disease in patients with type 1 diabetes. *Diabetes Care*. 2014;37(1):144–8.
  13. Ortiz F, Harjutsalo V, Helanterä I, Lempinen M, Forsblom C, Groop PH. Long-term mortality after kidney transplantation in a nationwide cohort of patients with type 1 diabetes in Finland. *Diabetes Care*. 2019;42(1):55–61.
  14. Harjutsalo V, Thomas MC, Forsblom C, Groop PH, Group FS. Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes. *Diabetes Obes Metab*. 2018;20(12):2759–67.
  15. Groop PH, Thomas M, Feodoroff M, Forsblom C, Harjutsalo V, Group FS. Excess mortality in patients with type 1 diabetes without albuminuria—separating the contribution of early and late risks. *Diabetes Care*. 2018;41(4):748–54.
  16. Trégouët DA, Heath S, Saut N, Biron-Andreani C, Schved JF, Pernod G, et al. Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. *Blood*. 2009;113(21):5298–303.
  17. Yamamoto F, McNeill PD, Hakomori S. Human histo-blood group A2 transferase coded by A2 allele, one of the A subtypes, is characterized by a single base deletion in the coding sequence, which results in an additional domain at the carboxyl terminal. *Biochem Biophys Res Commun*. 1992;187(1):366–74.
  18. Parmar AS, Alakulppi N, Paavola-Sakki P, Kurppa K, Halme L, Färkkilä M, et al. Association study of FUT2 (rs601338) with celiac disease and inflammatory bowel disease in the Finnish population. *Tissue Antigens*. 2012;80(6):488–93.
  19. Salem RM, Todd JN, Sandholm N, Cole JB, Chen WM, Andrews D, et al. Genome-wide association study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen. *J Am Soc Nephrol*. 2019;30(10):2000–16.
  20. Marie D, Sow MS, Diack A, Dia K, Mboup MC, Fall PD, Fall MD, et al. Cardiovascular disease and ABO blood-groups in Africans. Are blood-group A individuals at higher risk of ischemic disease?: A pilot study. *Egypt Heart J*. 2017;69(4):229–34.
  21. Blais C, Germain M, Delage G, Grégoire Y. The association between blood group and the risk of vascular disease in Quebec blood donors. *Blood Transfus*. 2016;14(5):455–9.
  22. Capuzzo E, Bonfanti C, Frattini F, Montorsi P, Turdo R, Previdi MG, et al. The relationship between ABO blood group and cardiovascular disease: results from the cardioprotect program. *Ann Transl Med*. 2016;4(10):189.
  23. Vasan SK, Rostgaard K, Majeed A, Ullum H, Titlestad KE, Pedersen OB, et al. ABO blood group and risk of thromboembolic and arterial disease: a study of 1.5 million blood donors. *Circulation*. 2016;133(15):1449–57.
  24. Medalie JH, Levene C, Papier C, Goldbourt U, Dreyfuss F, Oron D, et al. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. *N Engl J Med*. 1971;285(24):1348–53.
  25. Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, et al. Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. *Hum Mol Genet*. 2010;19(9):1863–72.
  26. Ferrer-Admetlla A, Sikora M, Laayouni H, Esteve A, Roubinet F, Blancher A, et al. A natural history of FUT2 polymorphism in humans. *Mol Biol Evol*. 2009;26(9):1993–2003.
  27. Rosenfeld ME, Campbell LA. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. *Thromb Haemost*. 2011;106(5):858–67.
  28. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. *Lancet Infect Dis*. 2010;10(2):83–92.
  29. Simonsen JR, Harjutsalo V, Järvinen A, Kirveskari J, Forsblom C, Groop PH, et al. Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study. *BMJ Open Diabetes Res Care*. 2015;3(1):e000067.
  30. Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, et al. Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease. *Circ Cardiovasc Genet*. 2014;7(1):43–8.
  31. Gourgari E, Ma J, Playford MP, Mehta NN, Goldman R, Remaley AT, et al. Proteomic alterations of HDL in youth with type 1 diabetes and their associations with glycemic control: a case-control study. *Cardiovasc Diabetol*. 2019;18(1):43.
  32. Svanteson M, Holte KB, Haig Y, Kløw NE, Berg TJ. Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography. *Cardiovasc Diabetol*. 2019;18(1):58.
  33. Song J, Chen F, Campos M, Bolgiano D, Houck K, Chambless LE, et al. Quantitative influence of ABO blood groups on factor VIII and its ratio to von Willebrand factor, novel observations from an ARIC study of 11,673 subjects. *PLoS ONE*. 2015;10(8):e0132626.
  34. Celik H, Duzenli U, Aslan M, Altıparmak IH, Kirit A, Kara E, et al. The relationship between platelet indices and ABO blood groups in healthy adults. *J Clin Lab Anal*. 2019;33(3):e22720.
  35. Karakas M, Baumert J, Kleber ME, Thorand B, Dallmeier D, Silbernagel G, et al. A variant in the ABO gene explains the variation in soluble E-selectin levels—results from dense genotyping in two independent populations. *PLoS ONE*. 2012;7(12):e51441.
  36. Paterson AD, Lopes-Virella MF, Waggott D, Boright AP, Hosseini SM, Carter RE, et al. Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. *Arterioscler Thromb Vasc Biol*. 2009;29(11):1958–67.
  37. Wittemans LBL, Lotta LA, Oliver-Williams C, Stewart ID, Surendran P, Karthikeyan S, et al. Assessing the causal association of glycine with risk of cardio-metabolic diseases. *Nat Commun*. 2019;10(1):1060.
  38. Ding Y, Svingen GF, Pedersen ER, Gregory JF, Ueland PM, Tell GS, et al. Plasma glycine and risk of acute myocardial infarction in patients with suspected stable angina pectoris. *J Am Heart Assoc*. 2015;5(1):e002621.
  39. Pike MM, Larson NB, Wassel CL, Cohoon KP, Tsai MY, Pankow JS, et al. ABO blood group is associated with peripheral arterial disease in African Americans: the multi-ethnic study of atherosclerosis (MESA). *Thromb Res*. 2017;153:1–6.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.